Register entry
- Registered sites
- 0
- Active NDC listings
- 26
- Live patents
- 0
- Countries
- 0
Catalogue
Drug listings by form and route
2626 active NDC listings: 22 drug for further processing, 4 human prescription drug. By marketing category: DRUG FOR FURTHER PROCESSING 22, ANDA 3, NDA 1.
| Dosage form | NDCs |
|---|---|
| injection, solution | 7 |
| injection, powder, lyophilized, for solution | 6 |
| injection, powder, for solution | 5 |
| injection | 4 |
| injection, solution, concentrate | 2 |
| injection, powder, lyophilized, for suspension | 1 |
| powder, for solution | 1 |
| Route | NDCs |
|---|---|
| intravenous | 4 |
| oral | 3 |
| Labeller name on the listing | NDCs |
|---|---|
| bamboo us bidco lcc | 26 |
Catalogue
Marketed products
26| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| - | Busulfan | injection | 83703-567DRUG FOR FURTHER PROCESSING |
| CYCLOPHOSPHAMIDE | cyclophosphamide | injection, powder, for solution, intravenous, oral | 83703-549ANDA |
| CYCLOPHOSPHAMIDE | cyclophosphamide | injection, powder, for solution, intravenous, oral | 83703-550ANDA |
| CYCLOPHOSPHAMIDE | cyclophosphamide | injection, powder, for solution, intravenous, oral | 83703-551ANDA |
| - | Datopotamab Deruxtecan | injection | 83703-530DRUG FOR FURTHER PROCESSING |
| MESNEX | mesna | injection, solution, intravenous | 83703-559NDA |
| - | Rituximab-abbs | injection, solution, concentrate | 83703-581DRUG FOR FURTHER PROCESSING |
| - | Rituximab-abbs | injection, solution, concentrate | 83703-582DRUG FOR FURTHER PROCESSING |
| - | brentuximab vedotin | powder, for solution | 83703-564DRUG FOR FURTHER PROCESSING |
| - | choriogonadotropin alfa | injection, powder, lyophilized, for solution | 83703-572DRUG FOR FURTHER PROCESSING |
| - | enfortumab vedotin | injection, powder, lyophilized, for solution | 83703-570DRUG FOR FURTHER PROCESSING |
| - | enfortumab vedotin | injection, powder, lyophilized, for solution | 83703-571DRUG FOR FURTHER PROCESSING |
| - | lurbinectedin | injection, powder, lyophilized, for solution | 83703-583DRUG FOR FURTHER PROCESSING |
| - | mecasermin | injection, solution | 83703-568DRUG FOR FURTHER PROCESSING |
| - | mecasermin | injection, solution | 83703-569DRUG FOR FURTHER PROCESSING |
| - | paclitaxel | injection, powder, lyophilized, for suspension | 83703-563DRUG FOR FURTHER PROCESSING |
| - | rituximab-arrx | injection, solution | 83703-573DRUG FOR FURTHER PROCESSING |
| - | rituximab-arrx | injection, solution | 83703-574DRUG FOR FURTHER PROCESSING |
| - | rituximab-arrx | injection, solution | 83703-575DRUG FOR FURTHER PROCESSING |
| - | rituximab-arrx | injection, solution | 83703-576DRUG FOR FURTHER PROCESSING |
| - | temozolomide | injection, powder, lyophilized, for solution | 83703-577DRUG FOR FURTHER PROCESSING |
| - | tisotumab vedotin | injection, powder, for solution | 83703-578DRUG FOR FURTHER PROCESSING |
| - | tisotumab vedotin | injection, powder, for solution | 83703-579DRUG FOR FURTHER PROCESSING |
| - | trastuzumab deruxtecan | injection, powder, lyophilized, for solution | 83703-580DRUG FOR FURTHER PROCESSING |
| - | zolbetuximab | injection | 83703-511DRUG FOR FURTHER PROCESSING |
| - | zolbetuximab | injection | 83703-516DRUG FOR FURTHER PROCESSING |
Compare
Other companies listing rituximab-arrx
- Amgen, Inc9 sites · 105 NDC
Enquiry
Common questions
- Is Bamboo US Bidco LCC FDA approved?
- Bamboo US Bidco LCC holds no registered establishment of its own; 26 drug products are listed under its name in the National Drug Code Directory, made at sites registered to other firms.
- What drugs does Bamboo US Bidco LCC make?
- 26 products are listed under Bamboo US Bidco LCC in the openFDA NDC Directory, most often as injection, solution; injection, powder, lyophilized, for solution; injection, powder, for solution. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.